People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Stentys adds regulatory exec: Paris-based start-up signals its intention to take the next steps in development of its coronary bifurcation lesion drug-eluting stent with the Feb. 21 appointment of Luc Morisset as director of regulatory affairs. Stentys plans to start feasibility studies by mid-year. Its technology allows a stent to open to a side branch vessel without relying on accurate positioning by the clinician, according to the firm. Morisset spent the last decade as director of regulatory affairs for MedPass International, a European medtech consulting firm. He also worked more than five years at the French Ministry of Health where he was involved in medical device approvals. Morisset joins CEO Gonzague Issenmann, who co-founded the firm in 2005 after leaving his position as finance controller for Johnson & Johnson/Cordis' European unit. Stentys co-founder and "non-executive" president Jacques Séguin is also currently CEO of Irvine, Calif.-based CoreValve, which is developing the ReValving system for percutaneous aortic valve replacement (1"The Gray Sheet" Oct. 30, 2006, p. 9)...
You may also be interested in...
Percutaneous Heart Valves May Demand Novel Regulatory Approach
Leading innovators hope to blaze a trail through what some see as formidable regulatory barriers to technological advances allowing diseased aortic valves to be replaced percutaneously
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.